[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598202":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":23,"locations":32,"responsibleParty":44,"collaborators":47,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":10,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":10,"maxAge":10,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":70,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Peking University People's Hospital","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"Retrospective cohort",null,"Patients whose first visit to our institution and the termination of follow-up both occurred before the opening of this study will contribute to the retrospective cohort.",{"label":13,"type":10,"description":14,"interventionNames":10},"Prospective cohort","Patients whose first visit to our institution occur after the opening of this study will contribute to the prospective cohort.",{"label":16,"type":10,"description":17,"interventionNames":10},"Retrospective\u002FProspective cohort","Patients whose first visit to our institution occurred before the opening of this study and whose follow-up will terminate after the opening of this study will contribute to the ambispective cohort.",[19],{"name":20,"affiliation":21,"role":22},"Xiao-Hui Zhang, MD","Peking University Institute of Hematology, Peking University People's Hospital","PRINCIPAL_INVESTIGATOR",[24,29],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Jin Wu, MD","CONTACT","086-01088326002","wujin1996@126.com",{"name":30,"role":26,"phone":27,"phoneExt":10,"email":31},"Li-Qin Cao, MD","caoliqin@pkuph.edu.cn",[33],{"facility":34,"status":10,"city":35,"state":10,"zip":10,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":10},"Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing 100010","Beijing","China","CN",{"type":39,"coordinates":40},"Point",[41,42],116.39723,39.9075,{"lat":42,"lon":41},{"type":22,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Xiao Hui Zhang","Vice President of Peking University Institute of Hematology Affiliation: Peking University People's Hospital",[48,50],{"name":49,"class":6},"Jiangsu Provincial People's Hospital",{"name":51,"class":6},"Wuhan TongJi Hospital","100598202","longitudinal-observational-study-on-immune-thrombocytopenia-100598202",false,"NCT07068425","Longitudinal Observational Study on Immune Thrombocytopenia","Retrospective and Prospective Longitudinal Observational Study on Immune Thrombocytopenia","Inclusion Criteria:\n\n1. Patients with confirmed diagnosis of ITP\n2. Patients treated at Peking University People's Hospital since January 1, 2005\n\nExclusion Criteria:\n\n1. Any condition that may render follow-up data unreliable, including but not limited to severe psychiatric disorders\"\n2. Patients deemed ineligible for the study by investigators\"",true,"ALL",{"count":62,"type":63},2000,"ESTIMATED","OBSERVATIONAL","Immune Thrombocytopenia (ITP) is a bleeding disorder characterized by immune-mediated destruction and\u002For impaired production of platelets, leading to clinical manifestations such as petechiae, purpura, mucosal bleeding, and in severe cases, life-threatening visceral or intracranial hemorrhage. Research on the diagnosis, treatment, and prognosis of ITP is critical for improving patient outcomes and quality of life. However, most existing hematologic cohort studies are limited to single-center or small multicenter samples, lacking comprehensive, large-scale prospective investigations.\n\nTo address this gap, our center plans to conduct a large-sample, combined retrospective and prospective longitudinal observational cohort study of ITP patients. The study will enroll patients to collect baseline demographic and diagnostic data, followed by longitudinal follow-up via questionnaires, telephone interviews, video consultations, online platforms, and in-person visits. Key variables including treatment regimens, comorbidities, and prognostic outcomes will be systematically recorded. Additionally, hospitalization and outpatient expenditure data will be extracted from electronic medical records.\n\nThis study aims to provide high-quality real-world evidence on the epidemiology, treatment patterns, clinical outcomes, and healthcare costs of ITP patients in China, ultimately informing clinical decision-making and health policy.",[67],"Immune Thrombocytopenia (ITP)",[69],"Immune Thrombocytopenia","NOT_YET_RECRUITING","2025-07-06",{"date":73,"type":74},"2025-07-16","ACTUAL",{"date":76,"type":63},"2025-07-10",{"date":78,"type":63},"2036-12-31",{"name":5,"class":6},1]